title: Complete loss of STAG2 expression is an indicator of good prognosis in patients with bladder cancer.
abstract: Stromal antigen 2 (STAG2) is an important member of cohesin, a conserved complex holding the sister chromatid together. Recent whole-genome sequencing studies have identified that genetic alterations of stag2 are common in bladder cancer (BC). The prognostic implications of STAG2 expression in BC remain unclear; we therefore analyzed its associations with the histopathological characteristics and clinical outcome in a Chinese population. We used immunohistochemistry assay to determine STAG2 protein expression in tumor tissues from 125 BC patients. STAG2 expression was analyzed according to clinicopathological features and patients' survival. Univariable and multivariable analyses were performed to identify predictors for recurrence-free survival (RFS) and cancer-specific survival (CSS). STAG2 expression was detected in 79.2 % of BC tissues, and 20.8 % of the tumor tissues had a complete loss of STAG2 protein expression. This STAG2-negative result was associated with a lower tumor histological grade with P = 0.009. The log-rank analysis revealed that the complete loss of STAG2 expression was associated with a lower risk of recurrence (P = 0.023) and a diminished risk of death (P = 0.034), especially in the subgroup of muscle-invasive BC (P = 0.043 for RFS and P = 0.087 for CSS). In multivariable Cox regression models, the loss of STAG2 expression remained a beneficial factor for RFS and CSS of BC patients. Univariate and multivariate analyses' results indicated that the complete loss of STAG2 expression was predictive for better RFS and CSS, suggesting its potential value as a prognostic biomarker.
authors.affiliation: Department of Laboratory Medicine, Peking University Third Hospital, Beijing, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Qiao
authors.affiliation: Department of Urology, Beijing Friendship Hospital Affiliated with Capital Medical University, Beijing, China.
authors.forename: Xi
authors.initials: X
authors.lastname: Zhu
authors.affiliation: Department of Laboratory Medicine, Peking University Third Hospital, Beijing, China.
authors.forename: Aiwei
authors.initials: A
authors.lastname: Li
authors.affiliation: Department of Laboratory Medicine, Peking University Third Hospital, Beijing, China.
authors.forename: Shuo
authors.initials: S
authors.lastname: Yang
authors.affiliation: Department of Laboratory Medicine, Peking University Third Hospital, Beijing, China. bjmuzhangjie@163.com.
authors.forename: Jie
authors.initials: J
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D034961:Antigens, Nuclear / Q000096:biosynthesis*; D044466:Asian People; D014408:Biomarkers, Tumor / Q000032:analysis*; D002295:Carcinoma, Transitional Cell / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D018797:Cell Cycle Proteins; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D001749:Urinary Bladder Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D000097722:Cohesins
chemical_list: D034961:Antigens, Nuclear; D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; C508565:STAG2 protein, human; D000097722:Cohesins
keywords: Bladder cancer; Cohesin; Prognosis; Stromal antigen
references.citation: Hum Mol Genet. 2014 Apr 15;23(8):1964-74
references.pmid: 24270882
references.citation: J Natl Compr Canc Netw. 2013 Apr 1;11(4):446-75
references.pmid: 23584347
references.citation: Genome Med. 2014 Jan 31;6(1):9
references.pmid: 24484537
references.citation: Nat Rev Cancer. 2014 Jun;14(6):389-93
references.pmid: 24854081
references.citation: Nat Genet. 2013 Dec;45(12):1459-63
references.pmid: 24121792
references.citation: Nat Genet. 2013 Dec;45(12):1464-9
references.pmid: 24121791
references.citation: Chin J Cancer Res. 2015 Feb;27(1):2-12
references.pmid: 25717220
references.citation: PLoS Biol. 2005 Mar;3(3):e69
references.pmid: 15737063
references.citation: Mol Cell Biol. 2011 Jun;31(11):2174-83
references.pmid: 21444719
references.citation: Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7
references.pmid: 16442208
references.citation: Eur Urol. 2015 Aug;68(2):238-53
references.pmid: 25709027
references.citation: PLoS Genet. 2014 Jul 10;10(7):e1004475
references.pmid: 25010205
references.citation: CA Cancer J Clin. 2015 Mar;65(2):87-108
references.pmid: 25651787
references.citation: Nat Genet. 2013 Dec;45(12):1428-30
references.pmid: 24121789
references.citation: CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71
references.pmid: 24890451
references.citation: Science. 2011 Aug 19;333(6045):1039-43
references.pmid: 21852505
references.citation: Urol Oncol. 2014 Oct;32(7):1078-87
references.pmid: 25217465
references.citation: J Biol Chem. 2004 Feb 20;279(8):6553-9
references.pmid: 14660624
references.citation: J Cell Biol. 2009 Oct 19;187(2):165-73
references.pmid: 19822671
references.citation: Eur Urol. 2009 Sep;56(3):430-42
references.pmid: 19576682
references.citation: J Cell Sci. 2014 Oct 1;127(Pt 19):4225-33
references.pmid: 25074805
references.citation: J Clin Oncol. 2006 Feb 10;24(5):778-89
references.pmid: 16432078